EPIC-HR
2022
Nirmatrelvir-Ritonavir in High-Risk Outpatients with COVID-19
In 2,246 high-risk unvaccinated adults with COVID-19, nirmatrelvir-ritonavir within 5 days of symptom onset reduced COVID-19-related hospitalisation or death by day 28 compared with placebo.
Result
- Absolute difference
- 5.54 points
relative reduction89
The absolute difference is derived from the event rates.
- Subtopic
- Outpatient antiviral
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Hammond J, et al. N Engl J Med. 2022;386(15):1397-1408.doi 10.1056/NEJMoa2118542
Discussion & critique
Cornerstone outpatient antiviral. Caveat: efficacy in vaccinated lower-risk patients and drug-drug interactions limit real-world impact.